Personalized Translational Platform for Biomarker Discovery in Brain Tumors

• Status: Completed
• Trial end date: 2016-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The central hypothesis for this proposal is that multimodal (clinical, imaging, tissue) biomarkers will better predict early brain tumor response to treatments and will be more reliable prognostic markers in patients with malignant brain tumors.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Marcelo F. Di Carli, MD, FACC
• Collaborators: General Electric; Society of Nuclear Medicine and Molecular Imaging

Criteria

Inclusion Criteria:

• Newly diagnosed or suspected high grade glioma ≥ 1cm in diameter on postoperative anatomic imaging (contrast MRI), prior to initiation of chemoXRT

• Anticipated survival ≥6 months

• Able to give informed consent

• Capable of undergoing MRI and PET scans without the need for sedation or general anesthesia

• Male or Female

Exclusion Criteria:

• Prior radiation therapy and chemotherapy to the brain

• Active intracranial infection or nonglial brain mass.

• Recent large intracranial hemorrhage (<1 month)

• Expected survival <6 months

• Pregnant or nursing

• Renal failure

• Lives far from BWH and/or is unwilling/ unable to return for scheduled imaging visits.